OHRPP Updates

Kip Kantelo, Director
October 12, 2017
NIH Policy on Single IRBs

- Policy coming this month released in June ‘16
- Effective for Jan May Sept Jan 25, 2018
- Domestic sites of multi-center
- Proposals to identify cIRB
  - Coordination plans & personnel
  - Certain direct costs allowable
NIH Policy on Single IRBs

- IRBrely SmartIRB framework
  - National agreement now in place
  - 200+ institutions (including UCLA)
  - Some institutions coming up with additional agreements
  - Online tool for communication

- RAND, UC, CTSI+USC, Commercial IRBs, one-offs
  - Commercial IRB scope expanded
NIH Policy on Single IRBs

- Challenges
  - IRB practices are not uniform
  - Institutional Policies
  - Ancillary Reviews
  - Communications among IRBs, IRB offices and study teams
  - Post-Approval Reporting
  - Costing

- Adapting will require extra work and communication
NIH Policy on Single IRBs

- UC-wide workgroups wrapping up, more detailed guidance and tools coming
- For Jan 25 proposals, contact us
  - irbreliance@research.ucla.edu
Final Rule

- Released January 19
- Effective next January (maybe)

Uncertainty
- Congressional review period expiry
- Administration review
- No clarifying guidance
- DOJ hasn’t signed on
- FDA hasn’t harmonized
- Other agencies with layers of policy
Final Rule

- On WH docket for 1 year delay
- Proposal to allow flex measures
  - Not officially known
  - No CR for expedited research
  - Some expansion of exemptions
  - No grant congruence requirement
Final Rule

- EVC’s HRPB Decisions
  - Replacing Continuing Review
    - Annual Administrative Ping
      - Study active
      - Reminders re amendments, PARs, closure
    - Study will be assumed closed if no response
  - Exemption Determinations
    - Remain with OHRPP
    - webIRB simplifications coming
Certificates of Confidentiality

- What CoCs used to be
- Sudden change
  - NIH only so far
- Coordinating announcement and changes
  - webIRB
  - Consent templates
  - ePass
Certificates of Confidentiality

- NIH-funded projects:
  - human subjects OR
  - very small risk of re-identification
- CoCs automatic
- Responsibilities
  - Protection from subpoena, etc
  - Extra care in releasing info
  - Notifying recipients, sub-awardees
  - Consent (where applicable)
FDA Expanded Access

- Certain categories of expanded access to drugs
- Easier, now along the lines of Emergency Use
  - Concurrence of IRB chair rather than IRB review
- Legal analysis in progress, assessing conflict with state law
Thank you!

❖ For questions:
  • Reliance
    ❑ irbreliance@research.ucla.edu
  • North & South General IRBs
    ❑ x57122
    ❑ gcirb@research.ucla.edu
  • Medical IRBs
    ❑ x55344
    ❑ mirb@research.ucla.edu